You just read:

Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released

News provided by

Shionogi & Co., Ltd.

Dec 01, 2016, 00:00 ET